Zobrazeno 1 - 10
of 23
pro vyhledávání: '"A. S. Protheroe"'
Autor:
Victoria K. Woodcock, Ji‐Li Chen, Karin Purshouse, Chrissie Butcher, Linda Collins, Caroline Haddon, Gillian Verrall, Leena Elhussein, Corran Roberts, Andrea Tarlton, Margarida Rei, Giorgio Napolitani, Mariolina Salio, Mark R. Middleton, Vincenzo Cerundolo, Jeremy Crew, Andrew S. Protheroe
Publikováno v:
BJUI Compass, Vol 4, Iss 3, Pp 322-330 (2023)
Abstract Objectives This study aimed to investigate the anti‐PD‐1 inhibitor pembrolizumab as a potential agent for use in non‐muscle‐invasive bladder cancer (NMIBC) by conducting a Phase 1 safety run‐in study to assess the safety and tolera
Externí odkaz:
https://doaj.org/article/d7395c1210aa4beeac995f4f6e98382c
Autor:
Karin Purshouse, Andrew S. Protheroe
Publikováno v:
Therapeutic Advances in Urology, Vol 11 (2019)
More than a million men worldwide are diagnosed with prostate cancer every year. After androgen deprivation therapy (ADT), chemotherapy has been the only subsequent intervention to improve survival in the metastatic setting but has limitations for pa
Externí odkaz:
https://doaj.org/article/ad327c4e8b0d47ad8b841914c20e4057
Autor:
Valentine M. Macaulay, Mark Howarth, Andrew S. Protheroe, Gareth D. Turner, Peter H. Thomas, Shan Gao, Olga V. Perestenko, Meenali M. Chitnis, Tamara Aleksic
Supplementary Materials, Table 1-2, Figures 1-3 from Type 1 Insulin-like Growth Factor Receptor Translocates to the Nucleus of Human Tumor Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7625a58e4f9acde079c2af1ad755fa0e
https://doi.org/10.1158/0008-5472.22382363.v1
https://doi.org/10.1158/0008-5472.22382363.v1
Autor:
Valentine M. Macaulay, Mark Howarth, Andrew S. Protheroe, Gareth D. Turner, Peter H. Thomas, Shan Gao, Olga V. Perestenko, Meenali M. Chitnis, Tamara Aleksic
The type 1 insulin-like growth factor receptor (IGF-1R) is a transmembrane glycoprotein composed of two extracellular α subunits and two β subunits with tyrosine kinase activity. The IGF-1R is frequently upregulated in cancers and signals from the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49509f84af497049facea57649b768b9
https://doi.org/10.1158/0008-5472.c.6500177
https://doi.org/10.1158/0008-5472.c.6500177
Autor:
Philip Earwaker, Caroline Anderson, Frances Willenbrock, Adrian L Harris, Andrew S Protheroe, Valentine M Macaulay
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0191890 (2018)
The outlook for patients with advanced renal cell cancer (RCC) has been improved by targeted agents including inhibitors of the PI3 kinase (PI3K)-AKT-mTOR axis, although treatment resistance is a major problem. Here, we aimed to understand how RCC ce
Externí odkaz:
https://doaj.org/article/a518e79ae27440dca778a61503dee383
Autor:
Nicholas D James, Fiona C Ingleby, Noel W Clarke, Claire L Amos, Gerhardt Attard, Christopher D Brawley, Simon Chowdhury, William Cross, David P Dearnaley, Duncan C Gilbert, Silke Gillessen, Robert J Jones, Ruth E Langley, Archie Macnair, Zafar I Malik, Malcolm D Mason, David J Matheson, Robin Millman, Chris C Parker, Hannah L Rush, J Martin Russell, Carly Au, Alastair W S Ritchie, Ricardo Pereira Mestre, Imtiaz Ahmed, Alison J Birtle, Susannah J Brock, Prantik Das, Victoria A Ford, Emma K Gray, Robert J Hughes, Caroline B Manetta, Duncan B McLaren, Ashok D Nikapota, Joe M O’Sullivan, Carla Perna, Clive Peedell, Andrew S Protheroe, Santhanam Sundar, Jacob S Tanguay, Shaun P Tolan, John Wagstaff, Jan B Wallace, James P Wylie, Anjali Zarkar, Mahesh K B Parmar, Matthew R Sydes
Publikováno v:
James, N D, Ingleby, F C, Clarke, N W, Amos, C L, Attard, G, Brawley, C D, Chowdhury, S, Cross, W, Dearnaley, D P, Gilbert, D C, Gillessen, S, Jones, R J, Langley, R E, Macnair, A, Malik, Z I, Mason, M D, Matheson, D J, Millman, R, Parker, C C, Rush, H L, Russell, J M, Au, C, Ritchie, A W S, Mestre, R P, Ahmed, I, Birtle, A J, Brock, S J, Das, P, Ford, V A, Gray, E K, Hughes, R J, Manetta, C B, McLaren, D B, Nikapota, A D, O'Sullivan, J M, Perna, C, Peedell, C, Protheroe, A S, Sundar, S, Tanguay, J S, Tolan, S P, Wagstaff, J, Wallace, J B, Wylie, J P, Zarkar, A, Parmar, M K B & Sydes, M R 2022, ' Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial ', JNCI Cancer Spectrum, vol. 6, no. 4, pkac043 . https://doi.org/10.1093/jncics/pkac043
Background STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic patients using, as primary outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00eff5f0fa14f1899d76357eb1c4d2a4
https://eprints.gla.ac.uk/276500/1/276500.pdf
https://eprints.gla.ac.uk/276500/1/276500.pdf
Autor:
Lennard Y W, Lee, Michael, Tilby, Thomas, Starkey, Maria C, Ionescu, Alex, Burnett, Rosie, Hattersley, Sam, Khan, Martin, Little, Justin K H, Liu, James R, Platt, Arvind, Tripathy, Isabella, Watts, Sophie Therese, Williams, Nathan, Appanna, Youssra, Al-Hajji, Matthew, Barnard, Liza, Benny, Andrew, Buckley, Emma, Cattell, Vinton, Cheng, James, Clark, Leonie, Eastlake, Kate, Gerrand, Qamar, Ghafoor, Simon, Grumett, Catherine, Harper-Wynne, Rachel, Kahn, Alvin J X, Lee, Anna, Lydon, Hayley, McKenzie, Hari, Panneerselvam, Jennifer, Pascoe, Grisma, Patel, Vijay, Patel, Vanessa, Potter, Amelia, Randle, Anne S, Rigg, Tim, Robinson, Rebecca, Roylance, Tom, Roques, Stefan, Rozmanowski, René L, Roux, Ketan, Shah, Martin, Sintler, Harriet, Taylor, Tania, Tillett, Mark, Tuthill, Sarah, Williams, Andrew, Beggs, Tim, Iveson, Siow Ming, Lee, Gary, Middleton, Mark, Middleton, Andrew S, Protheroe, Matthew W, Fittall, Tom, Fowler, Peter, Johnson, Remarez, Sheehan
Publikováno v:
JAMA Oncology. 9:188
ImportanceAccurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is not known whether SARS-CoV-2 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef02a74334ce35b8032d1323bc82c7d0
https://doi.org/10.1001/jamaoncol.2022.5974
https://doi.org/10.1001/jamaoncol.2022.5974
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Autor:
Miranda Payne, Mark R. Middleton, Elena Collantes, Sreedhar Subramanian, Joseph J. Sacco, Sarah C. Sasson, Jonathan Heseltine, Alison Simmons, Anna Olsson-Brown, Mark Tuthill, Cheung Vtf., Eve Fryer, Tarun Gupta, Paul Klenerman, A S Protheroe, Oliver Brain, Meenali Chitnis, Munir Pirmohamed, Benjamin P. Fairfax
Publikováno v:
British Journal of Cancer
Background Immune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse events (irAE). We sought to determine if CTCAE classification, IBD biomarkers/endoscopic/histological scores correlate with irAE colitis outcomes. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7fe15e127ac53c73fa25c05b1c06c0f
https://pubmed.ncbi.nlm.nih.gov/32418993
https://pubmed.ncbi.nlm.nih.gov/32418993
Autor:
S. Powell, David Carruthers, T Southwood, Deva Situnayake, V Paisal, D. Mitton, S Protheroe, E Al-Abadi
Publikováno v:
Poster Presentations.
Background Behcet Disease (BD) is rarely reported in children. It a systemic inflammatory condition characterised by autoinflammatory and vasculitic clinical features including recurrent oral aphthosis, genital ulceration, skin, eye, neurological and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8596349ce15dac2794e67fca4b88161
https://doi.org/10.1136/annrheumdis-2017-eular.6077
https://doi.org/10.1136/annrheumdis-2017-eular.6077